Vivani Medical, Inc. develops miniaturized, long-term biopharmaceutical implants aimed at improving medication adherence for chronic disease treatment. The company's primary product is the NanoPortal™ implant technology, which delivers steady doses of medication over extended periods. Vivani's lead drug candidates include NPM-139, a semaglutide implant for chronic weight management, and NPM-133, a semaglutide implant for type 2 diabetes. The company focuses on addressing challenges associated with medication non-adherence and tolerability in patients with chronic conditions.
- Website
- vivani.com
- Issuer profile
- All listings